文献速递泌尿生殖与妇科肿瘤放疗

高体积前列腺穿刺阳性芯数占比与5次立体定向体部放疗单药治疗后癌症复发风险增加无关

High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy.
PubMed 文献 · Radiat Oncol · 2024-03-04

本研究基于单机构大型数据库,纳入2009至2018年接受5次立体定向体部放疗(SBRT)且未使用雄激素剥夺治疗的1590例局限性前列腺癌患者,评估高体积穿刺芯受累(≥50%)与生化进展的关系。中位随访超过4年,高体积芯受累与生化进展无显著关联(p=0.234)。作者认为,在前列腺SBRT和MRI引导穿刺时代,高体积芯受累作为不利中危疾病的独立预测因子应被重新审视。

要点

  • 1590例接受5次SBRT单药治疗的患者中,高体积穿刺芯受累(≥50%)占19%。
  • 高体积芯受累与生化进展无显著关联(p=0.234)。
  • 中危队列中低体积芯受累者PSA最低值更高(p=0.004)。

核心结论

  • 中位随访超过4年,接受5次SBRT单药治疗的患者中,治疗前高体积穿刺芯受累与生化进展无显著关联(p=0.234)。
  • 作者认为,在前列腺SBRT和MRI引导前列腺穿刺时代,使用高体积芯受累作为不利中危疾病的独立预测因子应被重新审视。

研究设计与样本

  • 单机构大型数据库分析,纳入2009至2018年诊断为局限性前列腺癌并接受5次SBRT且未使用雄激素剥夺治疗的患者1590例。
  • 复习病理结果以确定详细芯受累情况及Gleason评分,高体积穿刺芯受累定义为≥50%。
  • 分析PSA动力学和肿瘤学结局与芯受累的关联。

主要发现

  • 高体积芯受累相对少见,在本队列中占19%,更多见于前列腺体积较小的患者(p < 0.0001)和/或中危疾病患者(p = 0.005)。
  • 中危队列中,低体积芯受累患者观察到更高的PSA最低值(p = 0.004);以Gleason评分加权的连续变量分析芯受累时亦得到证实(p = 0.049)。
  • 高体积芯受累与生化进展无显著关联(p = 0.234)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Percentage of positive cores involved on a systemic prostate biopsy has been established as a risk factor for adverse oncologic outcomes and is a National Comprehensive Cancer Network (NCCN) independent parameter for unfavorable intermediate-risk disease. Most data from a radiation standpoint was published in an era of conventional fractionation. We explore whether the higher biological dose delivered with SBRT can mitigate this risk factor. METHODS: A large single institutional database was interrogated to identify all patients diagnosed with localized prostate cancer (PCa) treated with 5-fraction SBRT without ADT. Pathology results were reviewed to determine detailed core involvement as well as Gleason score (GS). High-volume biopsy core involvement was defined as ≥ 50%. Weighted Gleason core involvement was reviewed, giving higher weight to higher-grade cancer. The PSA kinetics and oncologic outcomes were analyzed for association with core involvement. RESULTS: From 2009 to 2018, 1590 patients were identified who underwent SBRT for localized PCa. High-volume core involvement was a relatively rare event observed in 19% of our cohort, which was observed more in patients with small prostates (p < 0.0001) and/or intermediate-risk disease (p = 0.005). Higher PSA nadir was observed in those patients with low-volume core involvement within the intermediate-risk cohort (p = 0.004), which was confirmed when core involvement was analyzed as a continuous variable weighted by Gleason score (p = 0.049). High-volume core involvement was not associated with biochemical progression (p = 0.234). CONCLUSIONS: With a median follow-up of over 4 years, biochemical progression was not associated with pretreatment high-volume core involvement for patients treated with 5-fraction SBRT alone. In the era of prostate SBRT and MRI-directed prostate biopsies, the use of high-volume core involvement as an independent predictor of unfavorable intermediate risk disease should be revisited.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lischalk JW, Sanchez A, Santos VF, et al. High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy. Radiat Oncol. 2024. PMID: 38439040. doi:10.1186/s13014-023-02397-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。